SWOBY (Swedish Orphan Biovitrum AB) Price-to-Tangible-Book: (As of Sep. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SWOBY Swedish Orphan Biovitrum AB SWOBY
67 GF Score
Price $24.29
GF Value $18.75
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Swedish Orphan Biovitrum AB Price-to-Tangible-Book?

As of today (2026-09-07), Swedish Orphan Biovitrum AB's share price is $24.2875. Swedish Orphan Biovitrum AB's Tangible Book per Share of Jun. 2026 for the quarter that ended in Jun. 2026 was $-2.88. Hence, Swedish Orphan Biovitrum AB's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Swedish Orphan Biovitrum AB's Price-to-Tangible-Book or its related term are showing as below:

During the past 13 years, Swedish Orphan Biovitrum AB's highest Price to Tangible Book Ratio was 118.39. The lowest was 32.67. And the median was 46.00.

SWOBY's Price-to-Tangible-Book is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.31
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Swedish Orphan Biovitrum AB's share price is $24.2875. Swedish Orphan Biovitrum AB's Book Value per Sharefor the quarter that ended in Jun. 2026 was $6.39. Hence, Swedish Orphan Biovitrum AB's P/B Ratio of today is 3.80.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Swedish Orphan Biovitrum AB Price-to-Tangible-Book Related Terms

Swedish Orphan Biovitrum AB Price-to-Tangible-Book Historical Data

* Premium members only.

The historical data trend for Swedish Orphan Biovitrum AB's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Swedish Orphan Biovitrum AB Price-to-Tangible-Book Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Swedish Orphan Biovitrum AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

SWOBY vs ZTS: Price-to-Tangible-Book Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Swedish Orphan Biovitrum AB Price-to-Tangible-Book vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Price-to-Tangible-Book falls into.


SWOBY
67GF Score
Swedish Orphan Biovitrum AB SWOBY
Price-to-Tangible-Book is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Swedish Orphan Biovitrum AB Price-to-Tangible-Book Calculation

Swedish Orphan Biovitrum AB's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Jun. 2026 )
=24.2875/-2.881
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price to Tangible Book=Market Cap/Tangible Equity
=Market Cap/(Total Stockholders Equity-Preferred Stock-Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?

Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued. The current stock price of $24.29 is trading 29.5% above its estimated GF Value™ of $18.75. GuruFocus considers Swedish Orphan Biovitrum AB to be Modestly Overvalued.

Key valuation signals for SWOBY:

  • Price-to-Tangible-Book:
  • GF Value™: $18.75 vs. price of $24.29 (29.5% above fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Swedish Orphan Biovitrum AB Business Description

Address Norra Stationsgatan 93A, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score

Get the complete analysis for SWOBY

Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.29
Price
$18.75
GF Value